BIBLIOGRAPHY
Cannon, C. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes. Insights from the TACTICS TIMI-18 Trial. J. Am. Coll. Cardiol., 41:43–48S, 2003.
Gum, P. A., Kottke-Marchant, K., Welsh, P. A. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol., 41:961–5, 2003.
Hans-Christoph, D., Bogousslavsky, J., Brass, L. M. et al. On behalf of the MATCH investigators: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet, 364: 331–3, 200.
Lange, R. A., and Hillis, L. D. Antiplatelet therapy for ischemic heart disease. N. Engl. J. Med., 350:27–80, 2003.
Khan, M. Gabriel. Cardiac Drug Therapy, sixth edition, W. B. Saunders, Philadelphia, 423, 2003.
Mehta, S. R., and Yusuf, F. Short and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J. Am. Coll. Cardiol., 41:79–88S, 2003.
Moliterno, D. J., and Chan, A. W. Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPIS-TENT, ADMIRAL, CADILLAC, and TARGET. J. Am. Coll. Cardiol., 41:49–54S, 2003.
Страницы: 1 | 2